Vigilant Capital Management’s CRISPR Therapeutics CRSP Stock Holding History

Vigilant Capital Management’s Portfolio CRSP Stock Details CRSP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	$17K	Hold	300	–	–	﹤0.01%	365
2023 Q1	$14K	Hold	300	–	–	﹤0.01%	365
2022 Q4	$12K	Sell	300 -473	-61%	-$25.1K	﹤0.01%	385
2022 Q3	$51K	Hold	773	–	–	﹤0.01%	285
2022 Q2	$47K	Hold	773	–	–	﹤0.01%	275
2022 Q1	$49K	Hold	773	–	–	﹤0.01%	295
2021 Q4	$59K	Hold	773	–	–	﹤0.01%	298
2021 Q3	$87K	Hold	773	–	–	0.01%	220
2021 Q2	$125K	Hold	773	–	–	0.01%	184
2021 Q1	$94K	Buy	773 +473	+158%	+$71.4K	0.01%	199
2020 Q4	$46K	Hold	300	–	–	﹤0.01%	231
2020 Q3	$25K	Buy	+300	New	+$26.6K	﹤0.01%	265

Other funds holding CRSP

AIM

ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return

NAMA

Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

NMC

NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Vigilant Capital Management's CRSP Position: Q2 2023 in Review

Vigilant Capital Management held its CRISPR Therapeutics (CRSP) position steady in Q2 2023 at 300 shares worth $17K. The position accounts for ﹤0.01% of the portfolio, ranked #365.

Vigilant Capital Management first reported a position in CRSP in Q3 2020 and has held it in 12 quarters since. The position peaked at $125K in Q2 2021. 418 funds tracked by Wall St. Rank hold CRSP as of Q2 2023.

Vigilant Capital Management held 300 shares of CRISPR Therapeutics worth $17K as of Q2 2023.
Vigilant Capital Management left its CRISPR Therapeutics share count unchanged in Q2 2023.
CRISPR Therapeutics made up ﹤0.01% of Vigilant Capital Management's portfolio in Q2 2023, its #365 holding.
Vigilant Capital Management first reported a position in CRISPR Therapeutics in Q3 2020 and has held it in 12 quarters since.
Vigilant Capital Management's CRISPR Therapeutics position peaked at $125K in Q2 2021.
418 funds tracked by Wall St. Rank held CRISPR Therapeutics as of Q2 2023.

Based on Vigilant Capital Management's 13F filing for Q2 2023, filed 8 Aug 2023.